The Pharmaceutical Benefits Scheme: Economic evaluation works ... but is not a panacea

Australian Prescriber

Volumn 25, Issue 6, 2002, Pages 126-127

  Lopert, Ruth ^a   Henry, David ^a  

^a UNIVERSITY OF NEWCASTLE   (Australia)

Author keywords

Cost of drugs; Drug regulation

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; SILDENAFIL;

AUSTRALIA; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DRUG COST; DRUG INDUSTRY; ECONOMIC EVALUATION; EDITORIAL; HEALTH INSURANCE; PRESCRIPTION;

EID: 0036915682     PISSN: 03128008     EISSN: None     Source Type: Journal    
DOI: 10.18773/austprescr.2002.124     Document Type: Editorial

References (9)

1. Commonwealth Department of Human Services and Health. Guidelines for the Pharmaceutical Industry on Preparation of Submissions to the Pharmaceutical Benefits Advisory Committee: Including Major Submissions Involving Economic Analyses. Canberra: Australian Government Publishing Service; 1995.
2. Productivity Commission. International Pharmaceutical Price Differences. Research Report. Canberra: AusInfo; 2001. http://www.pc.gov.au/research/studies/pbsprices/finalreport/index.html
3. PBS Prescription Volume and Government Cost, year ending December 2001. http://www.health.gov.au/pbs/pubs/pbbexp/pbdec/bookp01.htm
4. Lopert R, Lang DL, Hill SR, Henry DA. Differential pricing of drugs: A role for cost-effectiveness analysis? Lancet 2002;359:2105-7.
5. Pillans PI, Kubler PA, Radford JM, Overland V. Concordance between use of proton pump inhibitors and prescribing guidelines. Med J Aust 2000;172:16-8.
6. http://www.health.gov.au/budget2002/fact/hfactl.htm.
7. Marley J. Cost-effectiveness: The need to know. Aust Prescr 1996;19: 58-9.
8. http://www.health.gov.au/pbs/listing/pbacrec/index.htm.
9. National Institute for Clinical Excellence. http://www.nice.org.uk.